Introduction
============

Although the incidence rate of gastric cancer (GC) has decreased \~3% per year in the last few decades, GC has been reported as the second leading cause of cancer-associated mortality worldwide, behind lung cancer in 2012 ([@b1-ol-0-0-10513]). Unfortunately, the majority of GC cases are diagnosed at an advanced stage; therefore, the clinical outcome of patients with GC remains poor and the 5-year survival rate of patients with advanced metastatic disease is \<30% ([@b2-ol-0-0-10513]). Therefore, the most effective treatment strategies for patients with advanced GC include chemotherapy and novel targeted therapies ([@b2-ol-0-0-10513]). Unlike other tumor types that have a number of therapeutic options based on the molecular characteristic of the tumor, the genomic landscape of GC is highly heterogeneous ([@b3-ol-0-0-10513]). Therefore, it can be difficult to target the entire GC tumor as sub-clones of GC cells possess different biological behaviors ([@b4-ol-0-0-10513]). In addition to Trastuzumab, an anti-human epidermal growth factor receptor 2 (HER2) antibody, and Ramucirumab, an anti-vascular endothelial growth factor receptor antibody ([@b5-ol-0-0-10513]), the Food and Drugs Administration (FDA) has recently approved Pembrolizumab, an anti-programmed cell death protein-1 (PD-1) antibody, for the treatment of patients with metastatic gastric cancer and high PD-L1 immunohistochemical expression ([@b6-ol-0-0-10513],[@b7-ol-0-0-10513]). Immunotherapy has revolutionized cancer treatment by introducing new therapies, including checkpoint inhibitors that target the host immune system instead of tumor cells ([@b8-ol-0-0-10513]).

The PD-1 and programmed death-ligand 1 (PD-L1) pathway is one of the most widely studied immune checkpoint pathways as it is crucial in physiological conditions for the maintenance of self-tolerance and preventing autoimmune diseases ([@b9-ol-0-0-10513]), and for evading antitumor immunity ([@b10-ol-0-0-10513]). PD-1 is an immune-inhibitory receptor that is constitutively expressed by activated T lymphocytes and macrophages, whereas other non-T lymphocytes, including B cells and natural killer cells, only express PD-1 following cytokine-induced stimulation ([@b11-ol-0-0-10513],[@b12-ol-0-0-10513]). In addition to being constitutively expressed by T cells, B cells, macrophages and dendritic cells, PD-L1 is also expressed on tumor cells (TCs) in several types of cancer. The interaction between PD-1 on T cells and PD-L1 on TCs inhibits the cluster of differentiation 8 (CD8)^+^ T cell-mediated immune response, which induces an immunosuppressive microenvironment within the tumor and promotes evasion of immune destruction ([@b12-ol-0-0-10513]). PD-1/PD-L1 inhibitors can restore antitumor immunity and immunotherapy using immune checkpoint inhibitors has been reported to be effective in certain cancer types, including malignant melanoma ([@b13-ol-0-0-10513]) and non-small cell lung cancer ([@b14-ol-0-0-10513]). However, the sensitivity to Pembrolizumab may not be the same in all patients eligible for immunotherapy; therefore, it may be useful to identify adjunctive biomarkers associated with the expression of PD-L1, which may allow a more accurate and targeted selection of eligible patients.

In colorectal cancer, it has been demonstrated that the majority of patients with mismatch repair deficiency (MMR-D) are good responders to anti-PD-1/PD-L1 therapy ([@b15-ol-0-0-10513],[@b16-ol-0-0-10513]). The mismatch repair (MMR) pathway is a DNA repair mechanism that recognizes and removes DNA replication errors. The loss of MMR proteins leads to an accumulation of DNA replication errors, which is termed microsatellite instability (MSI) ([@b17-ol-0-0-10513]). Proteins translated from genes with DNA replication errors can be immunogenic and provoke an antitumor immune response by increasing immune cell infiltration, which improves the sensitivity to PD-1/PD-L1 blockade therapy ([@b15-ol-0-0-10513],[@b16-ol-0-0-10513]).

The Cancer Genome Atlas Research Network revealed that PD-L1 gene amplification was higher in Epstein Barr virus (EBV)^+^ GC ([@b18-ol-0-0-10513]). In 1990, Burke *et al* ([@b19-ol-0-0-10513]) first reported an association between EBV status and the occurrence of GC with a characteristic lymphoepithelioma-like histology.

The expression of PD-L1 on the surface of TCs and in immune cells can be evaluated by immunohistochemistry (IHC) and serve as a predictive biomarker to identify patients that may benefit from immunotherapy; however, it has been identified that not all patients with a PD-L1^+^ status respond well to immunotherapy ([@b20-ol-0-0-10513]). Therefore, PD-L1 expression on TCs is currently considered an imperfect predictor of the response to immune checkpoint inhibitor therapy ([@b15-ol-0-0-10513]). For this reason, a number of studies have begun to investigate the tumor microenvironment, particularly focusing on the extent of tumor immune cell infiltration ([@b7-ol-0-0-10513],[@b15-ol-0-0-10513],[@b21-ol-0-0-10513]--[@b23-ol-0-0-10513]). An immunological classification of tumors into four different tumor microenvironment immune types (TMITs) based on PD-L1 status and low/high CD8^+^ tumor infiltrating lymphocyte (TIL) density has been proposed and validated in melanoma ([@b24-ol-0-0-10513],[@b25-ol-0-0-10513]). However, to the best of our knowledge, few studies have applied this classification in GC ([@b26-ol-0-0-10513],[@b27-ol-0-0-10513]). To promote a more accurate selection of patients, the present study evaluated PD-L1 expression in the tumor microenvironment and quantified tumor infiltrating CD8^+^ T cell density in a number of GC cases characterized by MMR-D, HER2 and EBV status.

Materials and methods
=====================

### Patients and tumor characteristics

A total of 46 males and 24 females (median age, 65.8 years; age range, 34--83 years) who underwent a curative gastrectomy for primary GC at the National Institute of Gastroenterology 'S. de Bellis' (Castellana Grotte, Italy) between 2014 and 2017 were included in the current study. The inclusion criteria included no previous chemotherapy, radiotherapy, Trastuzumab therapy or anti-PD-1/PD-L1 treatment prior to surgery. The pathological and clinical features of the patients are presented in [Table I](#tI-ol-0-0-10513){ref-type="table"}. The tumor site was proximal (cardias, corpus and fundus) in 37 patients and distal (antrum/pylorus) in 33 patients. According to the Lauren classification ([@b21-ol-0-0-10513],[@b22-ol-0-0-10513],[@b28-ol-0-0-10513]), the histological types of the 70 GC cases included 36 diffuse and 34 intestinal. Other pathological characteristics of the GC cases are summarized in [Table I](#tI-ol-0-0-10513){ref-type="table"}. The present study was approved by the Review Board of National Institute of Gastroenterology (Castellana Grotte, Italy) and was conducted in accordance with the Declaration of Helsinki. Prior to enrollment, all participants provided written informed consent.

Paraffin-embedded sections (4-µm-thick) were fixed with 10% neutral buffered formalin at room temperature for 24--48 h, immunostained, and *in situ* hybridization assays were performed. For each tumor, the histological subtype and tumor stage were reevaluated from hematoxylin and eosin (H&E)-stained slides ([@b29-ol-0-0-10513]) using a light microscope (magnification, ×5-40). Age, sex, nodal status and quantification of infiltrating immune cells (IICs), which encompass intratumoral and peritumoral lymphocytes, macrophages and plasma cells, were obtained from pathology reports and review of H&E slides. IICs were evaluated as 'mild' when few cells (30--40 cells) were stained within the tumor and/or at the tumor-stroma interface (not deforming the distance between the glands), and 'marked' (\>100 cells) when the infiltrate exhibited a greater density with a tendency to flow into plaques and infiltrate the neoplastic epithelium, deforming the distance between the glands.

Survival time was defined as the time from the date of surgery to the date of mortality or of the last successful interview. The median follow-up time was 24 months (range, 3--168 months). Patients who succumbed to the disease due to complications of the surgical procedure during the perioperative period or contact was lost prior to the first interview were excluded from the survival analysis.

### IHC staining

IHC was performed on 10% neutral buffered formalin-fixed (room temperature for 24--48 h), paraffin-embedded sections (4-µm-thick). IHC with anti-PD-L1 (cat. no. 13684S, clone E1L3N; Cell Signaling Technology, Inc., Danvers, MA, USA) diluted 1:800 at room temperature for 30 min was performed as previously described ([@b23-ol-0-0-10513]).

IHC with anti-CD8 (cat. no. M7103, Mab C8/144B; 1:200; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA), anti-MutL homolog 1 (MLH1; cat. no. M3640, Mab ES05; 1:50; Dako Agilent Technologies, Inc. Santa Clara, CA, USA) and anti-HER2 (polyclonal antibody, cat. no. A0485; 1:200; Dako; Agilent Technologies, Inc.) was analyzed on an automated autostainer (Dako; Agilent Technologies, Inc.). Briefly, sections were dewaxed in an oven for 20 min at 60°C, followed by two washes with xylene. The sections were then rehydrated in a graded alcohol series (ethanol 99, 95, 70%) and incubated with 3% hydrogen peroxide for 10 min at room temperature to block endogenous peroxidase activity. Sections were incubated with EDTA buffer (pH 8) at 98°C for 30 min for CD8 and MLH1 staining, and with 10 mM citrate buffer (pH 6) at 98°C for 30 min for HER2 staining. Monoclonal antibodies against CD8 and MLH1, and a polyclonal antibody against HER2 were incubated with the tissue sections (30 min at room temperature). PBS alone was used as the negative control. Dako Real ENVISION (cat. no. K5007; Dako; Agilent Technologies, Inc.) was used as visualization reagent (30 min at room temperature) and 3,3′-diaminobenzidine as chromogen (10 min at room temperature), according to the manufacturer´s protocol.

PD-L1 immunoreactivity was randomly evaluated separately for TCs and IICs. Cells were counted in 5 randomly-selected fields. PD-L1 positivity was defined as ≥5% positive cells with membrane staining of any intensity ([@b30-ol-0-0-10513]). Cytoplasmic staining was not considered in the present study. For the evaluation of CD8, five fields (radius, 150 µm) in the intratumoral and peritumoral areas were selected. The number of positive cells was counted and the median number of CD8^+^ T lymphocytes was used as the cut-off value to classify low/high CD8^+^ TIL cases of GC ([@b31-ol-0-0-10513]). Tumors with no MLH1 staining in the TC nuclei were defined as MMR deficient, while tumors with nuclear staining were classified as MMR proficient (MMR-P). HER2 status was evaluated as previously described by Hofmann *et al* ([@b32-ol-0-0-10513]). All IHC staining was independently scored by two pathologists, Dr Raffaele Armentano and Dr Maria Lucia Caruso from the Department of Pathology (National Institute of Gastroenterology 'S. de Bellis', Research Hospital, Castellana Grotte, Italy).

### HER2 chromogenic in situ hybridization (CISH)

Cases with an IHC score of 2+ for HER2 were subjected to CISH for the evaluation of HER2 gene amplification. CISH was performed using the ZytoDot2C SPEC ERBB2/CEN17 probe kit (ZytoVision GmBH, Bremerhaven, Germany). Tissue sections (4 µm-thick) were deparaffinized, incubated in pretreatment buffer for 15 min at 98--100°C and then washed with distilled water. Following enzymatic digestion for 15 min at room temperature, sections were dehydrated and incubated with 15 µl HER2 probe at 80°C for 5 min for denaturation and then at 37°C overnight for hybridization in a Thermobrite Hybridizer (StatSpin, Norwood, MA, USA). To prevent evaporation during incubation, standard coverslips and rubber cement were used. Following removal of the coverslips, the slides were washed in stringent wash buffer for 5 min at 75°C. HER2 gene amplification was detected by sequential incubation with anti-DIG/DNP-mix, HRP/AP-Polymer-mix, AP-Red solution and HRP-Green solution. Finally, the slides were counterstained with hematoxylin (1 min at room temperature). Sections of breast cancer tissue known to be HER2-amplified were included as the positive control in each run.

The CISH signal was evaluated using a light microscope (magnification, ×40) following review of the H&E and IHC stained slides to identify areas of invasive GC with the strongest intensity of HER2 expression. The TC nuclei were evaluated to calculate the ratio of HER2 to centromere 17 (CEN-17) signals. HER2 amplification was defined as a HER2/CEN-17 ratio ≥2. If the ratio was \<2, an average number of HER2 signals per cell count \<4 indicated no HER2-amplification and an average number of signals per cell count \>6 indicated HER2 amplification. A mean average ≥4 and \<6 indicated an equivocal result. For an equivocal result performing IHC or CISH in a different patient sample was recommended ([@b33-ol-0-0-10513]). For the evaluation of HER2 status, cases with an IHC score of 3+ or 2+ with gene amplification were regarded as HER2^+^ and the remaining cases were defined as HER2^−^.

### EBV status

CISH for EBV-encoded RNA (EBER) was performed using an RNAscope detection kit (Advanced Cell Diagnostics, Newark, CA, USA), according to the manufacturer\'s protocol. Tissue sections (4-µm-thick) were baked at 60°C for 1 h and then deparaffinized. Deparaffinized slides were boiled for 10 min with citric buffer (pH 6.0) for antigen retrieval. Slides were further permeabilized by protease treatment at 40°C for 30 min in a HybEZ hybridization oven (Advanced Cell Diagnostics), followed by hybridization with the target probe, amplification and detection by adding Amp1-4. Chromogenic detection was performed using 3,3′-diaminobenzidine followed by counterstaining with hematoxylin (1 min at room temperature). The kit included slides with HeLa cultured cells that were used as a positive or negative control depending on the probes adopted for hybridization. Samples stained brown in any TC nuclei were considered positive by using a light microscope (magnification, ×10 and ×20).

### Statistical analysis

Continuous variables are presented as the mean ± standard deviation and categorical variables are presented as the relative frequency (%). To investigate associations between the categorical variables a χ^2^ test or Fisher\'s exact test were used, depending on the sample size. For non-parametric variables, analyses were performed by Mann-Whitney U test or Kruskal-Wallis test. The post hoc test used was Mann Whitney U with Bonferroni\'s correction test. For survival analysis, Kaplan-Meier analysis followed by a Wilcoxon-Breslow test and log-rank test was used to evaluate the importance of single variables as prognostic factors associated with survival. P\<0.05 was considered to indicate a statistically significant difference. All statistical analysis was performed using STATA v.12.1 statistical software (StataCorp LP, College Station, TX, USA).

Results
=======

### PD-L1 immunohistochemical expression

Different percentages of PD-L1 were observed on TCs and IICs. All non-neoplastic gastric epithelia were identified to be PD-L1^−^. Among the 70 patients, 8 cases (11%) were revealed to possess PD-L1^+^ TCs ([Table I](#tI-ol-0-0-10513){ref-type="table"}), the majority of which revealed a patchy pattern and rarely a diffused one. PD-L1 immunoreactivity on TCs was significantly associated with a greater density of IICs (P\<0.05).

Furthermore, PD-L1 immunoreactivity was detected in IICs in 40% of GC cases ([Table I](#tI-ol-0-0-10513){ref-type="table"}) and was present within the tumor and at the interface between the tumor and surrounding stroma, with a prevalently patchy pattern. Representative images of PD-L1 immunohistochemical expression on TCs and IICs are presented in [Fig. 1A and B](#f1-ol-0-0-10513){ref-type="fig"}, respectively. A total of six (75%) TC PD-L1^+^ GC cases were also IIC PD-L1^+^, while 35% of PD-L1^−^ GCs were IIC PD-L1^+^ (P\<0.05; [Table I](#tI-ol-0-0-10513){ref-type="table"}). PD-L1 positivity in IICs was significantly higher in the intestinal-type cases of GC compared with the diffuse-type cases (56 vs. 25%, P\<0.05) and significantly higher in GC cases with a pushing pattern of growth compared with cases with an infiltrating pattern of growth (64 vs. 34%; P\<0.05; [Table I](#tI-ol-0-0-10513){ref-type="table"}).

### HER2 immunohistochemical expression and association with PD-L1 staining

HER2 positivity was observed in 19 (27%) samples (13 IHC score, 3+; 6 IHC score, 2+/gene amplified; [Fig. 2A and B](#f2-ol-0-0-10513){ref-type="fig"}). A total of 51 HER2- tumors (25 IHC score, 0; 23 IHC score, 1; three IHC score, 2+ not amplified) were identified ([Table II](#tII-ol-0-0-10513){ref-type="table"}). Among the HER2^+^ samples, one (5%) sample was PD-L1^+^ on TCs and IICs, seven (37%) were positive only on IICs, and eleven (58%) were negative on the two. No significant association was revealed between PD-L1 expression and HER2 status ([Table I](#tI-ol-0-0-10513){ref-type="table"}).

### MLH1 immunohistochemical expression and association with PD-L1 staining

MLH1 deficiency was observed in seven (10%) cases and was more frequent in PD-L1^+^ GC cases compared with PD-L1^−^ GC cases. Four (57%) GC cases that were PD-L1^+^ on TCs were MLH1 deficient, whereas 43% of PD-L1^−^ TC GC cases were MLH1 deficient (P\<0.05; [Table I](#tI-ol-0-0-10513){ref-type="table"}). All GC cases that were MMR deficient were PD-L1^+^ on IICs, whereas 33% of MMR proficient GC cases were PD-L1^+^ on IICs (P\<0.05; [Table I](#tI-ol-0-0-10513){ref-type="table"}).

### EBV status

Among the 70 patients, two (3%) were positive for EBV infection. The histological features demonstrated poorly differentiated adenocarcinomas with a relatively rich lymphocyte infiltration. EBV^+^ cases demonstrated intense nuclear staining. EBV positivity was observed in all tumoral cells aggregated in cords, which was clearly surrounded by EBV^−^ lymphocytes ([Fig. 3](#f3-ol-0-0-10513){ref-type="fig"}). No cases revealed positivity for EBV in the non-tumoral mucosa. The two EBV^+^ samples were PD-L1^+^ on TCs (P\<0.05; [Table II](#tII-ol-0-0-10513){ref-type="table"}).

### CD8 immunohistochemical expression and TMITs

CD8^+^ lymphocytes were present within tumor-cell nests and intratumoral and peritumoral stroma. In total, 16 (23%) GC cases with a high CD8^+^ TILs density were identified and 54 (77%) GC cases were revealed to have a low CD8^+^ TILs density. The cases that were PD-L1^+^ on TCs more frequently featured a high CD8^+^ TILs density compared with the PD-L1^−^ cases (P\<0.05; [Table I](#tI-ol-0-0-10513){ref-type="table"}), and the two EBV^+^ samples had a high CD8^+^ high density (P\<0.05; [Table II](#tII-ol-0-0-10513){ref-type="table"}).

Based on the results of immunohistochemical expression of PD-L1 on TCs and CD8^+^ TILs density, the patients were categorized into the TMIT subgroups I--IV ([@b34-ol-0-0-10513]). The number and proportion in each TMIT were as follows: five (7%) type I (PD-L1^+^/CD8^+^ high; [Fig. 4](#f4-ol-0-0-10513){ref-type="fig"}), 51 (73%) type II (PD-L1^−^/CD8^+^ low), three (4%) type III (PD-L1^+^/CD8^+^ low); eleven (16%) type IV (PD-L1^−^/CD8^+^ high). TMITs were significantly associated with pattern of growth, MMR status and EBV status ([Table III](#tIII-ol-0-0-10513){ref-type="table"}).

### Survival analysis

Survival data were available for 32 patients. The median follow-up time was 24 months (range, 3--168 months). During follow-up, 19 patients succumbed to GC and 13 were alive at the last date of follow-up. No significant associations were revealed with survival time (data not shown).

Discussion
==========

Certain studies have demonstrated that PD-L1 is highly expressed on TCs and IICs in GC ([@b26-ol-0-0-10513],[@b35-ol-0-0-10513]--[@b38-ol-0-0-10513]). However, the prognostic significance of PD-L1 remains controversial and its role as a therapeutic predictor requires further investigation.

A recent immune checkpoint blockade has received much attention for prolonging survival of patients with GC ([@b39-ol-0-0-10513]). In the KEYNOTE-059 study, a phase II trial, 259 patients with advanced refractory GC received Pembrolizumab until progression. The overall response rate was 15.5% in PD-L1^+^ patients versus 5.5% in PD-L1^−^ patients. The threshold of PD-L1 immunohistochemical positivity was 1% and took into account staining on TCs and IICs ([@b39-ol-0-0-10513]). Following the results of this trial, the FDA approved Pembrolizumab for the treatment of patients with locally advanced or metastatic gastric, or gastroesophageal junction cancer in which TCs express PD-L1 (cut-off \>1%) ([@b6-ol-0-0-10513]). Since not all patients who are determined as eligible for a targeted therapy demonstrate equal sensitivity, patient selection may be improved by taking into account PD-L1 expression in addition to other available biomarkers.

Furthermore, in accordance with the strategy of combining immunotherapy and targeted therapy, two recent multicenter studies have investigated the antitumor activity and safety of Pembrolizumab in combination with anti-HER2 agents in patients with HER2^+^ GC. The available data are at an early stage; however, high response rates and the preliminary overall survival data justify the interest associated with PD-1 inhibitors, which indicates immunotherapy may serve a significant role in GC ([@b40-ol-0-0-10513]).

To gain more in-depth information, the present study investigated PD-L1 expression in the tumor gastric microenvironment, and evaluated its association with HER2, MMR and EBV status. In agreement with previous studies ([@b21-ol-0-0-10513],[@b35-ol-0-0-10513],[@b36-ol-0-0-10513]), the current study identified a higher expression level of PD-L1 on IICs (40%) compared with TCs (11%). In previous studies, PD-L1 on TCs was detected in 14--74% of patients with GCs ([@b22-ol-0-0-10513],[@b26-ol-0-0-10513],[@b34-ol-0-0-10513],[@b38-ol-0-0-10513],[@b41-ol-0-0-10513]) compared with 30--88% on IICs ([@b21-ol-0-0-10513],[@b35-ol-0-0-10513]). The wide range of PD-L1 expression reported in previous studies may be explained by the different antibodies used to detect PD-L1 or the evaluation methods used to define PD-L1 positivity. The present study used the monoclonal antibody E1L3N from Cell Signaling Technology, Inc. as it is considered to have a higher sensitivity compared with other PD-L1 antibodies ([@b42-ol-0-0-10513]). The cut-off value for PD-L1 remains controversial. However, the majority of studies investigating GC evaluated the expression of PD-L1 using a 1 or 5% cut-off value ([@b26-ol-0-0-10513],[@b35-ol-0-0-10513],[@b36-ol-0-0-10513],[@b38-ol-0-0-10513]). The latter value was used in the current study since minimal PD-L1 expression may have no effect on tumor biology ([@b35-ol-0-0-10513]).

Although the present study had a number of intrinsic limitations, our group has ample experience and has published various articles regarding different aspects of the PD-1/PD-L1 pathway ([@b23-ol-0-0-10513],[@b43-ol-0-0-10513]). A number of previous studies indicate that immunohistochemical positivity should be considered with caution ([@b32-ol-0-0-10513],[@b33-ol-0-0-10513]), particularly when it is used for the selection of patients suitable for therapy. Previously, extensive evaluations of markers with a cutoff \>1% have been replaced by different markers as they were ineffective, for example, the use of epidermal growth factor receptor and K-Ras has evolved over time in targeted therapy with Cetuximab ([@b44-ol-0-0-10513],[@b45-ol-0-0-10513]).

Furthermore, certain studies consider cytoplasmic positivity for the purpose of evaluating positive cases ([@b46-ol-0-0-10513],[@b47-ol-0-0-10513]). By contrast, it has repeatedly been stressed that membrane positivity is the only indicator of a receptor\'s presence ([@b48-ol-0-0-10513]). Unlike the strict immunohistochemical evaluation of HER2 in mammary and gastric carcinomas, to the best of our knowledge, precise guidelines do not exist for PD-L1, including for the evaluation of PD-L1 expression on biopsy material. However, the prevalent focal pattern of PD-L1 suggests immunohistochemical analysis should be performed on multiple biopsies to avoid underestimating the expression of PD-L1.

In the present study, the majority of patients who were PD-L1^+^ on TC demonstrated PD-L1 positivity on IICs, which suggests that PD-L1 expression in GCs is predominantly controlled by an adaptive immune resistance induced by immune cells via interferon-γ secretion rather than by an intrinsic pathway ([@b25-ol-0-0-10513]). However, 31% of GCs were only PD-L1+ on IICs. PD-L1 is constitutively expressed in certain immune cells, including lymphocytes, macrophages and dendritic cells ([@b49-ol-0-0-10513]); however, it can also be induced by inflammatory cytokines ([@b25-ol-0-0-10513]). This likely reflects the combined effect of innate and adaptive, and cellular and soluble factors present in the tumor microenvironment ([@b50-ol-0-0-10513]). Certain studies have reported a positive association between PD-L1 expression on IICs and the response to PD-1 inhibitor treatment, which supports the use of PD-L1 expression as a predictive marker for immunotherapy ([@b42-ol-0-0-10513],[@b51-ol-0-0-10513]).

The positive association between PD-L1 expression on IICs and intestinal type GC may be due to the different pathogenesis of intestinal and diffuse histological types ([@b52-ol-0-0-10513]). The present study suggests that the multistep carcinogenic pathway, caused by carcinogens, from chronic gastric inflammation to intestinal type cancer could exert a greater and more prolonged stimulation of the immune system, including mucosa-associated lymphoid tissue, which eventually becomes self-limited and induces the expression of PD-L1.

In agreement with Kawazoe *et al* ([@b47-ol-0-0-10513]), the present study demonstrated that PD-L1 expression on TCs and/or IICs was not associated with clinicopathological characteristics of poor prognosis. In addition, PD-L1 expression on TCs was identified to be significantly associated with high CD8^+^ TIL density, which is associated with adaptive resistance. This indicates that the tumor cells expressing PDL-1 in response to the cytokines produced by the TILs are able to escape the immune response of the host through the binding to PD-1 in T cells ([@b25-ol-0-0-10513]). By contrast, no association was revealed between PD-L1 expression on IICs and high CD8^+^ TILs, which indicates that the IICs are not only composed of CD8^+^ T lymphocytes.

Furthermore, the current study evaluated the MMR status only by an assessment of MLH1 protein expression, as it was lost in \>90% of GCs with MSI ([@b4-ol-0-0-10513]). In the present study, the percentage of GCs with MMR-D (10%) was consistent with a previous study that reported a frequency of 10--20% ([@b4-ol-0-0-10513]). In agreement with previous studies ([@b35-ol-0-0-10513],[@b43-ol-0-0-10513]), the current study demonstrated a significant association between MMR-D and PD-L1 expression on TCs and IICs. This finding can be explained as MMR deficient tumors are considered to be highly immunogenic due to the heavy mutation-associated-neoantigens burden, which is responsible for adaptive immune resistance ([@b15-ol-0-0-10513],[@b16-ol-0-0-10513]).

A number of studies support the hypothesis that TILs exhibit a tumor prognostic value and an 'immunoscore', which takes into account CD3^+^ and CD8^+^ TILs, has been demonstrated to be a powerful prognostic and therapeutic indicator ([@b21-ol-0-0-10513],[@b53-ol-0-0-10513]). To identify which patients are suitable for immunotherapy, a new classification of tumors has recently been proposed, based on PD-L1 status on TCs and the presence/absence of TILs ([@b24-ol-0-0-10513],[@b25-ol-0-0-10513]). This classification was developed to improve understanding of the tumor immune microenvironment. However, the tumor microenvironment is particularly complex and several critical issues have to be considered for the interaction between PD-L1 and TILs, including density, location and lymphocytes subpopulations. This classification was considered too simplistic and was later modified using immunohistochemical positivity for CD8 as a surrogate marker for TILs ([@b34-ol-0-0-10513]). The new classification consists of the four following TMITs: I (PD-L1^+^/CD8^+^ high, adaptive immune resistance), II (PD-L1^−^/CD8^+^ low, immune ignorance type), III (PD-L1^+^/CD8^+^ low, intrinsic induction of PD-L1) and IV (PD-L1^−^/CD8^+^ high, tolerant tumors), which indicates the role of other suppressors in promoting immune tolerance ([@b24-ol-0-0-10513]). The proportion of various cancer types that fit into each of these types likely depends on other genetic aberrations and oncogene drivers, as well as the type of tissue in which they originate ([@b25-ol-0-0-10513]).

Malignant melanoma has been extensively studied and a high proportion of type I and II microenvironments has been reported ([@b25-ol-0-0-10513]). Clinical studies have demonstrated that \~38% of patients with advanced melanoma with a type I profile are sensitive to anti-PD-L1 treatment. By contrast, patients with melanoma with a type II tumor microenvironment are not responsive to checkpoint blockade ([@b25-ol-0-0-10513]). To the best of our knowledge, similar information regarding GC remains unknown.

The present study classified patients with GC into the TMITs I--IV based on the results of PD-L1 expression on TCs and CD8^+^ TIL density. In agreement with previous studies ([@b21-ol-0-0-10513],[@b54-ol-0-0-10513]), it was identified that the majority of GC cases belong to TMIT II (73%), which is the immune ignorance type. Previous studies that have described TMITs in GC revealed that the highest percentage of tumors were type II ([@b21-ol-0-0-10513],[@b27-ol-0-0-10513]); however, a higher frequency was identified in the present study. This may be due to the cut-off value of 5% used in the current study, which can lead to the identification of a larger number of negative cases compared with studies that used a cut-off value of 1%. A low level of CD8^+^ TILs may partially explain the high mortality rate of patients with GC and restrict the use of antibodies that target immune checkpoints.

In agreement with previous studies ([@b21-ol-0-0-10513],[@b27-ol-0-0-10513]), the current study demonstrated that TMIT I GC cases are associated with EBV infection and MSI status, which are characterized by heavy lymphocytic infiltration ([@b19-ol-0-0-10513]). EBERs are the most abundant latency-associated transcripts in EBV-infected cells ([@b55-ol-0-0-10513]). Notably, EBERs are very stable in formalin-fixed paraffin-embedded tissues, which makes them sensitive EBV markers ([@b55-ol-0-0-10513]). CISH of EBER has been reported to be beneficial for the detection of EBV-infected cells ([@b56-ol-0-0-10513]). The RNAscope is a novel RNA-ISH platform that makes use of a novel probe design strategy and a hybridization-based signal amplification system that can theoretically yield up to 8,000 labels for each target RNA molecule, resulting in high definition signals ([@b57-ol-0-0-10513]). The percentage of positive EBER GC cases identified in the present study (3%) was lower compared with that reported in a previous study (7--10%) ([@b18-ol-0-0-10513]), which may be due to the limited number of lymphoepithelioma-like cases. In the current study, EBER was exclusively detected in the TC compartment, and not in lymphocytes and stromal cells, which is consistent with a previous study ([@b18-ol-0-0-10513]). Furthermore, a high rate of infiltration of CD8^+^ T cells is a characteristic of EBV^+^ GC cases ([@b58-ol-0-0-10513]). The EBV^+^ GC cases in the present study were associated with high densities of CD8^+^ TILs and belonged to TMIT I. TMIT I status involves adaptive immune escape responses and previous studies suggest that GC cases with this signature can be reversed by immune checkpoint blockade ([@b24-ol-0-0-10513],[@b59-ol-0-0-10513]).

TMIT III was identified as the least frequent category, which demonstrates that constitutive expression of PD-L1 on TCs through oncogenic signaling is not an important phenomenon in GC. This group could include patients who exhibit positive PD-L1 expression on neoplastic cells but do not respond to therapy ([@b25-ol-0-0-10513]). GC cases of TMIT IV contain a high CD8^+^ TILs density, however, do not demonstrate obvious adaptive resistance, as neoplastic gastric cells do not express PD-L1.

Tumeh *et al* ([@b60-ol-0-0-10513]) reported that for patients with stage III malignant melanoma, a predictive marker of clinical response to PD-1 blockade is the density of CD8^+^ TILs and not PD-L1 expression itself. This could explain the responsiveness to therapy of patients with negative PD-L1 expression on TCs.

Furthermore, in the present study, an association between PD-L1 and HER2 was not identified. Li *et al* ([@b22-ol-0-0-10513]) reported that PD-L1 expression on GC TCs is associated with HER2 expression; however, the study did not specify if the samples were HER2^−^ or HER2^+^. Oki *et al* ([@b61-ol-0-0-10513]) demonstrated that PD-L1+ GC cases were associated with an increasing HER2 score. These previous studies did not make a distinction between HER2^+^ versus HER2^−^ samples. Despite correctly evaluating the positivity of HER2, according to Hofmann\'s criteria ([@b32-ol-0-0-10513]), Böger *et al* ([@b35-ol-0-0-10513]), Ju *et al* ([@b30-ol-0-0-10513]) and Wang *et al* ([@b36-ol-0-0-10513]) reported contradictory results regarding the association between PD-L1 and HER2.

In agreement with a previous study ([@b62-ol-0-0-10513]), the present study revealed that 10.5% of HER2^+^ GC samples versus 12% of HER^−^ GC samples exhibited PD-L1 expression on TCs. No HER2^+^ sample was identified to be MMR deficient. The Research Network of The Cancer Genome Atlas data demonstrated that HER2 amplification was more common in tumors with chromosomal instability compared with microsatellite instability ([@b18-ol-0-0-10513]). Therefore, the positive association between PD-L1 and MMR status may explain the low probability of identifying GC samples positive for PD-L1 and HER2.

In GC, the association between PD-L1 expression and survival remains to be fully understood ([@b35-ol-0-0-10513],[@b41-ol-0-0-10513],[@b63-ol-0-0-10513],[@b64-ol-0-0-10513]). Fang *et al* ([@b41-ol-0-0-10513]) demonstrated that PD-L1 expression on TCs was not associated with overall survival, while patients with PD-L1 expression on TILs had a significantly shorter 5-year overall survival rate compared those with negative PD-L1 expression. A recent study of a large cohort of Caucasian patients with GC revealed that PD-L1 expression in tumor and stromal immune cells was associated with improved survival ([@b34-ol-0-0-10513]), while previous studies of an Asian population revealed a poor prognostic role of PD-L1 ([@b63-ol-0-0-10513],[@b64-ol-0-0-10513]). Apart from the difference of ethnicity, these studies were performed in heterogeneous populations, which contained patients with various stages of cancer that were undergoing different treatment strategies in different clinical settings.

In the present study, the small number of samples did not allow any significant differences in survival time to be identified between PD-L1^+^ and PDL1^−^ patients, even when taking into account the TMITs. In conclusion, the current results, which require validation with a larger sample size, may highlight a subset of patients with GC who exhibit PD-L1 expression on TCs, a high density of CD8^+^ TILs and MMR deficiency. To the best of our knowledge, for the first time the present study demonstrated that a positivity of EBER, detected using the RNAscope method, may be useful for predicting the effectiveness of anti-PD-1/PD-L1 antibody therapy.

Not applicable

Funding
=======

This study was supported by the Italian Ministry of Health, Ricerca Corrente 2018.

Availability of data and materials
==================================

All data analyzed during this study are included in this article.

Authors contributions
=====================

AMV and MLC conceived and designed the study. FDP and SC collected samples for immunohistochemical analysis and performed the immunohistochemical staining. AMV and RA were responsible for immunohistochemical evaluation. VG analyzed the data. FDP prepared the figures. AMV and MLC wrote the paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate
==========================================

The present study was approved by the Institutional Review Board (National Institute of Gastroenterology 'S. de Bellis', Research Hospital, Castellana Grotte, Bari, Italy) and was conducted in accordance with the Declaration of Helsinki. Prior to enrollment, all parti cipants provided written informed consent.

Patient consent for publication
===============================

Not applicable.

Competing interests
===================

The authors declare that they have no competing interests.

GC
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![Programmed death-ligand 1 immunoreactivity on (A) tumor cells and (B) infiltrating immune cells. Magnification, ×200.](ol-18-02-1775-g00){#f1-ol-0-0-10513}

![HER2 staining of gastric cancer cells. (A) HER2 immunohistochemical staining revealed a strong membranous pattern in neoplastic gastric cells with a score of 3+. Magnification, ×200. (B) HER2 gene amplification is indicated by green clusters. Magnification, ×400. HER2, human epidermal growth factor receptor 2.](ol-18-02-1775-g01){#f2-ol-0-0-10513}

![EBER CISH. EBER CISH demonstrated positive nuclei in the GC cells, which are surrounded by infiltrating lymphocytes. Magnification, ×100. EBER, Epstein Barr virus-encoded RNA; CISH, chromogenic *in situ* hybridization.](ol-18-02-1775-g02){#f3-ol-0-0-10513}

![Staining of a tumor microenvironment immune type I GC sample. A programmed death-ligand 1^+^ GC sample with a high cluster of differentiation 8^+^ T lymphocyte density. Magnification, ×100. Inset magnification, ×200. GC, gastric cancer.](ol-18-02-1775-g03){#f4-ol-0-0-10513}

###### 

Association between PD-L1 expression and clinicopathological characteristics.

                                                                           PD-L1 TCs     PD-L1 IICs                                                                                         
  ---------------------------------------------------------- ------------- ------------- --------------- ------------------------------------------------------ ------------- ------------- ------------------------------------------------------
  Sex                                                                                                    NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^                                   NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^
    Female                                                   24 (34.00)    3 (12.50)     21 (87.50)                                                               9 (37.50)   15 (62.50)    
    Male                                                     46 (66.00)    5 (11.00)     41 (89.00)                                                             19 (41.00)    27 (59.00)    
  Age, years^[a](#tfn1-ol-0-0-10513){ref-type="table-fn"}^   65.83±10.63   70.75±11.40   65.19±10.45     NS^[d](#tfn4-ol-0-0-10513){ref-type="table-fn"}^       67.39±10.99   65.12±10.27   NS^[d](#tfn4-ol-0-0-10513){ref-type="table-fn"}^
  Tumor site                                                                                             NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^                                   NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^
    Distal                                                   33 (47.00)    3 (9.00)      30 (91.00)                                                             13 (39.00)    20 (61.00)    
    Proximal                                                 37 (53.00)    5 (13.50)     32 (86.50)                                                             15 (40.50)    22 (59.50)    
  Histological type                                                                                      NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^                                   \<0.05^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^
    Diffuse                                                  36 (51.00)    5 (14.00)     31 (86.00)                                                               9 (25.00)   27 (75.00)    
    Intestinal                                               34 (49.00)    3 (9.00)      31 (91.00)                                                             19 (56.00)    15 (44.00)    
  Tumor grade (65)                                                                                       NS^[c](#tfn3-ol-0-0-10513){ref-type="table-fn"}^                                   NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^
    G1+G2                                                    12 (17.00)    0 (0.00)        12 (100.00)                                                            6 (50.00)     6 (50.00)   
    G3                                                       58 (83.00)    8 (14.00)     50 (86.00)                                                             22 (38.00)    36 (62.00)    
  Pattern of growth                                                                                      NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^                                   \<0.05^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^
    Pushing                                                  14 (20.00)    3 (21.00)     11 (79.00)                                                               9 (64.00)     5 (36.00)   
    Infiltrating                                             56 (80.00)    5 (9.00)      51 (91.00)                                                             19 (34.00)    37 (66.00)    
  Tumor Budding                                                                                          NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^                                   NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^
    Absent                                                   25 (36.00)    2 (8.00)      23 (92.00)                                                             13 (52.00)    12 (48.00)    
    High                                                     45 (64.00)    6 (13.00)     39 (87.00)                                                             15 (33.00)    30 (67.00)    
  IICs                                                                                                   \<0.05^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^                               NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^
    Mild                                                     45 (64.00)    2 (4.00)      43 (96.00)                                                             15 (33.00)    30 (67.00)    
    Marked                                                   25 (36.00)    6 (24.00)     19 (76.00)                                                             13 (52.00)    12 (48.00)    
  pT status                                                                                              NS^[c](#tfn3-ol-0-0-10513){ref-type="table-fn"}^                                   NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^
    T1-T2                                                    10 (14.00)    0 (0.00)      10 (100.00)                                                              4 (40.00)     6 (60.00)   
    T3-T4                                                    60 (86.00)    8 (13.00)     52 (87.00)                                                             24 (40.00)    36 (60.00)    
  pN status                                                                                              NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^                                   NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^
    N0                                                       13 (19.00)    3 (23.00)     10 (77.00)                                                             7 (54.00)       6 (46.00)   
    N+                                                       57 (81.00)    5 (9.00)      52 (91.00)                                                             21 (37.00)    36 (63.00)    
  MMR status                                                                                             \<0.05^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^                               \<0.05^[c](#tfn3-ol-0-0-10513){ref-type="table-fn"}^
    Deficient                                                  7 (10.00)   4 (57.00)       3 (43.00)                                                            7 (100.00)    0 (0.00)      
    Proficient                                               63 (90.00)    4 (6.00)      59 (94.00)                                                             21 (33.00)    42 (67.00)    
  HER2 status                                                                                            NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^                                   NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^
    Positive                                                 19 (27.00)    2 (10.50)     17 (89.50)                                                               8 (42.00)   11 (58.00)    
    Negative                                                 51 (73.00)    6 (12.00)     45 (88.00)                                                             20 (39.00)    31 (61.00)    
  CD8^+^                                                                                                 \<0.05^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^                               NS^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^
    High                                                     16 (23.00)    5 (31.00)     11 (69.00)                                                               7 (44.00)     9 (56.00)   
    Low                                                      54 (77.00)    3 (5.50)      51 (94.50)                                                             21 (39.00)    33 (61.00)    
  PDL1 TCs                                                                                               --                                                                                 \<0.05^[b](#tfn2-ol-0-0-10513){ref-type="table-fn"}^
    Positive                                                   8 (11.00)   --            --                                                                       6 (75.00)     2 (25.00)   
    Negative                                                 62 (89.00)    --            --                                                                     22 (35.00)    40 (65.00)    

Data presented as the mean ± standard deviation. Data were analyzed by

χ^2^ test

Fisher\'s exact test or

Mann-Whitney U test. NS, not significant; PD-L1, programmed death-ligand 1; TC, tumor cell; IIC, infiltrating immune cell; HER2, human epidermal growth factor receptor 2; MMR, mismatch repair; CD8, cluster of differentiation 8.

###### 

Association between EBV status, PD-L1 expression and CD8^+^ TILs density.

                         PD-L1 TCs   PD-L1 IICs   CD8+ TILs                                                  
  ------------ --------- ----------- ------------ ----------- ---------- ---------- ---- --------- --------- --------
  EBV status                                      \<0.05                            NS                       \<0.05
    Positive   2 (3)     2 (100)     0 (0)                      1 (50)     1 (50)        2 (100)   0 (0)     
    Negative   68 (97)   6 (0)         62 (100)               27 (40)    41 (60)         14 (21)   54 (79)   

Data were analyzed by

Fisher\'s exact test or

χ^2^ test. NS, not significant; PD-L1, programmed death-ligand 1; TC, tumor cell; IIC, infiltrating immune cell; EBV, Epstein Barr virus; TIL, tumor infiltrating lymphocyte.

###### 

Association between TMIT and clinicopathological characteristics.

                                                                           TMIT                                                      
  ---------------------------------------------------------- ------------- ------------- --------------- ------------- ------------- -------------------------------------------------------
  Sex                                                                                                                                NS^[b](#tfn9-ol-0-0-10513){ref-type="table-fn"}^
    Female                                                   24 (34.00)    1 (4.00)      15 (62.50)      2 (8.00)      6 (25.50)     
    Male                                                     46 (66.00)    4 (9.00)      36 (78.00)      1 (2.00)      5 (11.00)     
  Age, years^[a](#tfn8-ol-0-0-10513){ref-type="table-fn"}^   65.83±10.63   65.50±14.39   64.60±10.66     76.00±4.76    67.67±9.53    NS^[c](#tfn10-ol-0-0-10513){ref-type="table-fn"}^
  Tumor site                                                                                                                         NS^[b](#tfn9-ol-0-0-10513){ref-type="table-fn"}^
    Distal                                                   33 (47.00)    1 (3.00)      24 (73.00)      2 (6.00)      6 (82.00)     
    Proximal                                                 37 (53.00)      4 (11.00)   27 (73.00)      1 (3.00)      5 (13.00)     
  Histological type                                                                                                                  NS^[b](#tfn9-ol-0-0-10513){ref-type="table-fn"}^
    Diffuse                                                  36 (51.00)      4 (11.00)   25 (69.00)      1 (3.00)      6 (17.00)     
    Intestinal                                               34 (49.00)    1 (3.00)      26 (76.00)      2 (6.00)      5 (15.00)     
  Tumor grade (65)                                                                                                                   NS^[d](#tfn11-ol-0-0-10513){ref-type="table-fn"}^
    G1+G2                                                    12 (17.00)    0 (0.00)        12 (100.00)   0 (0.00)      0 (0.00)      
    G3                                                       58 (83.00)    5 (9.00)      39 (70.00)      3 (5.00)      11 (16.00)    
  Pattern of growth                                                                                                                  \<0.05^[d](#tfn11-ol-0-0-10513){ref-type="table-fn"}^
    Pushing                                                  14 (20.00)    1 (7.00)        9 (64.00)       3 (22.00)   1 (7.00)      
    Infiltrating                                             56 (80.00)    4 (7.00)      42 (75.00)      0 (0.00)      10 (18.00)    
  Tumor budding                                                                                                                      NS^[d](#tfn11-ol-0-0-10513){ref-type="table-fn"}^
    Absent                                                   25 (36.00)    0 (0.00)      20 (80.00)      2 (8.00)      3 (12.00)     
    High                                                     45 (64.00)      5 (11.00)   31 (69.00)      1 (2.00)      8 (18.00)     
  pT status                                                                                                                          NS^[d](#tfn11-ol-0-0-10513){ref-type="table-fn"}^
    T1-T2                                                    10 (14.00)    0 (0.00)        9 (90.00)     0 (0.00)        1 (10.00)   
    T3-T4                                                    60 (86.00)    5 (8.00)      42 (70.00)      3 (5.00)      10 (17.00)    
  pN status                                                                                                                          NS^[b](#tfn9-ol-0-0-10513){ref-type="table-fn"}^
    N0                                                       13 (19.00)    1 (8.00)        8 (61.50)     1 (8.00)      3 (22.50)     
    N+                                                       57 (81.00)    4 (7.00)      43 (75.00)      2 (3.50)      8 (14.50)     
  MMR status                                                                                                                         \<0.05^[d](#tfn11-ol-0-0-10513){ref-type="table-fn"}^
    Deficient                                                  7 (10.00)     2 (28.50)   3 (43.00)         2 (28.50)   0 (0.00)      
    Proficient                                               63 (90.00)    3 (5.00)      48 (76.00)      1 (2.00)      11 (17.00)    
  HER2 status                                                                                                                        NS^[b](#tfn9-ol-0-0-10513){ref-type="table-fn"}^
    Positive                                                 19 (27.00)    1 (5.00)      15 (79.00)      1 (5.00)      2 (10.50)     
    Negative                                                 51 (73.00)    4 (8.00)      36 (71.00)      2 (4.00)      9 (17.00)     
  EBV status                                                                                                                         \<0.05^[d](#tfn11-ol-0-0-10513){ref-type="table-fn"}^
    Positive                                                 2 (3.00)      2 (100.00)    0 (0.00)        0 (0.00)      0 (0.00)      
    Negative                                                 68 (97.00)    3 (4.00)      51 (75.00)      3 (4.00)      11 (17.00)    

Data presented as the mean ± standard deviation. Data were analyzed by

χ^2^ test

Kruskal-Wallis test or

Fisher\'s exact test. NS, not significant; TMIT, tumor microenvironment immune type; HER2, human epidermal growth factor receptor 2; MMR, mismatch repair; EBV, Epstein Barr virus.
